
Joshua Cohen
Contributor at Forbes
Health economist, researcher and writer on healthcare policy, drug pricing and reimbursement, political centrist, weather nut, diehard Red Sox and Bruins fan.
Articles
-
2 days ago |
forbes.com | Joshua Cohen
In this photo illustration, packages of mifepristone tablets are displayed at a family planning ... More clinic. Mifepristone is part of a two-drug regimen to induce an abortion in the first trimester of pregnancy in combination with the drug misoprostol. (Photo illustration by Anna Moneymaker/Getty Images)Getty ImagesThe abortion pill mifepristone is in the crosshairs of politics again, as plaintiffs in several high-profile court cases together with Republican lawmakers push for restrictions.
-
2 days ago |
forbes.com | Joshua Cohen
President Donald Trump signs an executive order. (Photo by ROBERTO SCHMIDT / AFP) (Photo by ROBERTO ...
-
3 days ago |
forbes.com | Joshua Cohen
Set to launch this month, a recently approved blood test to detect biomarkers for Alzheimer’s disease could bring diagnosis into everyday clinical practice. In turn, this may support earlier intervention approaches that may help patients, their families and caregivers. The diagnostic, called a Lumipulse G Plasma Ratio test, is the first of its kind to get marketing clearance from the Food and Drug Administration.
-
3 days ago |
forbes.com | Joshua Cohen
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024.
-
4 days ago |
forbes.com | Joshua Cohen
At the May annual meeting of the World Health Organization’s members in Geneva, Switzerland, officials and delegates spoke of the potential disruption that could be caused by the organization’s budget crisis. They expressed concerned about possible program cuts that could lead to substantial increases in burden of disease and deaths globally.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 4K
- DMs Open
- No

RT @berlin_bridge: Last night Russia attacked a European capital with ballistic missiles and hundreds of drones. Today the story barely reg…

RT @SaraForTexLege: Kyiv is currently under heavy attack because we have a feckless leader who is capitulating to a fascist dictator. He’s…

RT @WUTangKids: The best 5 minutes you’ll spend on this hellsite today….Bill Burr with some serious real talk! https://t.co/ohcBcemljy